Lawless, Sarah, Sbianchi, Giulia, Morris, Curly, Iacobelli, Simona, Bosman, Paul, Blaise, Didier, Remenyi, Peter, Byrne, J. L., Mayer, Jiri, Apperley, Jane, Lund, Johan, Kobbe, Guido, Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Basak, Grzegorz, Touzeau, Cyrille, Wilson, Keith M. O., Gonzalez Muniz, Soledad, Scheid, Christof, Browne, Paul, Anagnostopoulos, Achilles, Rambaldi, Alessandro, Jantunen, Esa, Kroeger, Nicolaus, Schoenland, Stefan, Yakoub-Agha, Ibrahim and Garderet, Laurent (2021). IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. Clin. Lymphoma Myeloma Leuk., 21 (10). S. 686 - 694. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Full text not available from this repository.

Abstract

The rare myelomas, immunoglobulin (Ig)D, IgM, and non-secretory, have been associated with poorer outcomes following treatment than the common myelomas (IgG, IgA, and light-chain only). We show that even with novel therapies, augmented with autologous transplantation, this remains true for IgD myeloma. In contrast, IgM and non-secretory myelomas have a prognosis similar to the usual myelomas. Background: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data. Patients: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with usual and rare myelomas. Results: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis. Conclusion: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes. (C) 2021 Elsevier Inc. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Lawless, SarahUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sbianchi, GiuliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Morris, CurlyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Iacobelli, SimonaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bosman, PaulUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blaise, DidierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Remenyi, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Byrne, J. L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayer, JiriUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Apperley, JaneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lund, JohanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kobbe, GuidoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaap, NicolaasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Isaksson, CeciliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lenhoff, StigUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Basak, GrzegorzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Touzeau, CyrilleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wilson, Keith M. O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gonzalez Muniz, SoledadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Browne, PaulUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Anagnostopoulos, AchillesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rambaldi, AlessandroUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jantunen, EsaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroeger, NicolausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoenland, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yakoub-Agha, IbrahimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Garderet, LaurentUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-606869
DOI: 10.1016/j.clml.2021.05.012
Journal or Publication Title: Clin. Lymphoma Myeloma Leuk.
Volume: 21
Number: 10
Page Range: S. 686 - 694
Date: 2021
Publisher: CIG MEDIA GROUP, LP
Place of Publication: DALLAS
ISSN: 2152-2669
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
MOBILIZATION; EFFICACY; AGENTSMultiple languages
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60686

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item